Editas Medicine (EDIT) Debt Ratio (2016 - 2025)
Editas Medicine (EDIT) posted quarterly Debt Ratio of 0.31 for Q4 2025, up 86.86% year-over-year from 0.17 in Q4 2024, and up 7.31% quarter-over-quarter from 0.29 in Q3 2025.
Powered by 
Analysis
Editas Medicine (EDIT) Debt Ratio (2016 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Debt Ratio for 4 consecutive years, with 0.31 the latest figure, recorded in Q4 2025.
- In Q4 2025, Debt Ratio rose 86.86% year-over-year to 0.31; the TTM figure through Dec 2025 stood at 0.31 (up 86.86% YoY), while the FY2025 annual figure was 0.31, up 86.86% from the prior year.
- Debt Ratio climbed to 0.31 in Q4 2025 per EDIT's latest filing, from 0.29 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.31 in Q4 2025 and bottomed at 0.17 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.05 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.47 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.26 |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - | 0.31 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 0.31 |
| Sep 30, 2025 | 0.29 |
| Jun 30, 2025 | 0.27 |
| Mar 31, 2025 | 0.21 |
| Dec 31, 2024 | 0.17 |
| Dec 31, 2017 | 0.02 |
| Jun 30, 2017 | 0.04 |
| Mar 31, 2017 | 0.04 |
| Dec 31, 2016 | 0.04 |